Université de Bordeaux, Département de médecine générale, 146 rue Léo Saignat, 33076 Bordeaux Cedex
Centre Hospitalier de Pau, service de maladies infectieuses, 4 boulevard Hauterive, 64000 Pau
Correspondance : S. Marot
HIV pre-exposure prophylaxis (PrEP) consists of the use of the combination of Tenofovir disoproxil fumarate and Emtricitabine, molecules used as anti-retroviral treatment, to prevent immunodeficiency virus (HIV) contamination in patients at risk. General practitioners who had until then been able to ensure quarterly renewal, can initiate and ensure follow-up on their own since June 1, 2021. This qualitative study aims to explore the place that patients on PrEP assign to their general practitioner in the management of this prophylaxis. It appears that patients are very satisfied with PrEP and the current specialized follow-up. They welcome the investment of GPs, to allow the dissemination of PrEP and facilitate follow-up. However, they expect from them an open discourse on sexuality and a good mastery of PrEP and the diagnostic and therapeutic management of sexually transmitted infections.